|Print Page Close Window|
Stockholder OverviewCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Since we began operations in November 2014, we have built a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. ...
NASDAQ CRVS (Common Stock)
$9.76 + 0.65 (7.14%)
08/15/1812:41 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
Corvus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update08/02/18
Corvus Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference07/31/18
Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, Immunotherapy06/28/18
Corvus Pharmaceuticals Inc at the 2018 Wedbush PacGrow Healthcare Conference08/15/18 8:35 a.m. ET